SCHEMBL3512082

SCHEMBL3512082

CC(C)C[C@H](N)C(=O)OC(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.55
SLC1A1 P43005 5/20 0.46
SLC1A3 P43003 5/20 0.46
SLC1A2 P43004 5/20 0.46
GRIK1 P39086 2/20 0.46
GRIK2 Q13002 2/20 0.46
GSR P00390 2/20 0.46
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
CYP1A2 P05177 1/20 0.46
GRM5 P41594 1/20 0.46
GRIA1 P42261 1/20 0.46
GRIA2 P42262 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIK3 Q13003 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9176437 0.95 SLC7A5 (0.50) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL1537429 0.90 SLC7A5 (0.44) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL27469444 0.88 SLC7A5 (0.42) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL15655614 0.86 SLC7A5 (0.50) SLC7A5SLC1A1SLC1A3SLC1A2FOLH1
SCHEMBL542258 0.86 SLC7A5 (0.50) SLC7A5SLC1A1SLC1A3SLC1A2FOLH1
SCHEMBL3510710 0.85 SLC1A1 (0.47) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL1444867 0.84 SLC1A1 (0.50) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL7717181 0.84 SLC1A1 (0.54) SLC1A1SLC1A3SLC1A2GRIK1GRIK2
SCHEMBL3430330 0.84 SLC1A1 (0.54) SLC1A1SLC1A3SLC1A2GRIK1GRIK2
SCHEMBL2994699 0.84 SLC1A1 (0.54) SLC1A1SLC1A3SLC1A2GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117157094-A Pharmaceutical composition for preventing or treating chronic kidney disease comprising glucagon derivative 韩美药品株式会社 2023-12-01 CN disclosed
US-10175233-B2 Biomarkers for cardiovascular diseases and methods using the same METABOLON, INC. (US) 2019-01-08 US disclosed
US-20160178620-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2016-06-23 US disclosed
WO-2016048828-A1 GENETICALLY MODIFIED MICROBES FOR THE BIOLOGICAL CONVERSION OF CARBONACEOUS MATERIALS TO ISOBUTANOL AND ISOAMYL ALCOHOL CIRIS ENERGY, INC. (US) 2016-03-31 WO disclosed
US-9250225-B2 Biomarkers for insulin resistance and methods using the same METABOLON, INC. (US) 2016-02-02 US disclosed
CN-103044542-B Serpin and gene thereof and application in crucian ovum CHANGSHU INSTITUTE OF TECHNOLOGY (CN) 2015-08-19 CN disclosed
US-20150005195-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2015-01-01 US disclosed
US-8809008-B2 Biomarkers for impaired glucose tolerance and methods using the same METABOLON, INC. (US) 2014-08-19 US disclosed
US-20130338031-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2013-12-19 US disclosed
EP-2164977-B1 BIOMARKERS FOR PRE-DIABETES AND METHODS USING THE SAME METABOLON INC (US) 2013-10-30 EP disclosed
EP-1601974-A2 DIFFERENTIAL MEGAPLEX IMMUNOASSAY TCP Innovations Limited (GB) 2005-12-07 EP disclosed
US-6846809-B2 PEI: DNA vector formulations for in vitro and in vivo gene delivery BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-01-25 US disclosed
WO-2004081025-A2 DIFFERENTIAL MEGAPLEX IMMUNOASSAY TCP INNOVATIONS LIMITED (GB) 2004-09-23 WO disclosed
EP-1355628-A2 STABILISED POLYMERIC AEROSOLS FOR PULMONARY GENE DELIVERY Board of Regents, The University of Texas System (US) 2003-10-29 EP disclosed
EP-1322337-A2 PEI : DNA VECTOR FORMULATIONS FOR IN VITRO AND IN VIVO GENE DELIVERY Board of Regents, The University of Texas System (US) 2003-07-02 EP disclosed
US-20020187105-A1 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-12-12 US disclosed
US-20020151060-A1 PEI: DNA vector formulations for in vitro and in vivo gene delivery BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-10-17 US disclosed
WO-2002060412-A2 STABILISED POLYMERIC AEROSOLS FOR PULMONARY GENE DELIVERY BOARD OF REGENTS (US) 2002-08-08 WO disclosed
WO-2002024232-A2 PEI: DNA VECTOR FORMULATIONS FOR IN VITRO AND IN VIVO GENE DELIVERY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-03-28 WO disclosed
US-4351337-A Biodegradable, implantable drug delivery device, and process for preparing and using the same ARTHUR D. LITTLE, INC. (US) 1982-09-28 US disclosed